GeneSight vs Genomind vs Gene2Rx: Three-Way Pharmacogenetic Test Comparison

If you are choosing between pharmacogenetic tests, the three names you are most likely to encounter are GeneSight, Genomind's Genecept Assay, and a handful of direct-to-consumer services including Gene2Rx. All three use the same underlying CPIC and FDA pharmacogenetic guidelines, so the fundamental science is shared. The practical differences are in cost, medication coverage, how each service is delivered, and which genes are included.

Made by Myriad Genetics. Requires a healthcare provider's order. Insurance-billed, with patient out-of-pocket typically capped around $330 for insured patients. Reports on approximately 60 medications, focused on psychiatric prescribing (antidepressants, antipsychotics, mood stabilizers, anxiolytics, ADHD medications). The test panel includes CYP2D6, CYP2C19, CYP2C9, CYP3A4, CYP1A2, CYP2B6, plus COMT, MTHFR, HTR2A, SLC6A4, HLA-A, HLA-B, UGT1A4, UGT2B15, and OPRM1. Its color-coded report (green, yellow, red) is the signature feature. As a clinical lab test it uses a fresh sample and clinical-grade assays.

Similar to GeneSight in delivery model: requires a provider's order, uses a new cheek swab, bills insurance. Genomind's panel emphasizes neuropsychiatric markers, including ADRA2A, CACNA1C, SLC6A4, and HLA variants alongside the core drug-metabolizing enzymes. Coverage extends to medications used in psychiatry, ADHD, chronic pain, and some neurological conditions. Total out-of-pocket cost varies widely by insurance and qualifying diagnosis.

Direct-to-consumer. Analyzes raw genetic data you already have from 23andMe, AncestryDNA, MyHeritage, or whole-genome sequencing. No provider order required. Priced $5 for a starter report, $35 for a psychiatric report, or $49 for the full report. Covers 110 medications across every major drug class where CPIC or FDA guidelines apply, including psychiatric medications plus cardiology, pain, oncology, transplant, gastroenterology, antivirals, and anticonvulsants. The panel includes CYP2D6, CYP2C19, CYP2C9, CYP3A4, CYP3A5, CYP2B6, CYP1A2, CYP2A6, CYP4F2, SLCO1B1, ABCG2, VKORC1, DPYD, TPMT, NUDT15, UGT1A1, COMT, and more. It does not test HLA alleles, or markers like MTHFR, HTR2A, SLC6A4, and OPRM1, because CPIC does not publish clinical dosing guidelines for those. Because it reads consumer genotyping or sequencing data rather than running a fresh clinical assay, it does not detect CYP2D6 copy-number changes.

If you are already seeing a psychiatrist who uses GeneSight in their practice, GeneSight is the simplest choice because the report format fits their prescribing workflow. If you specifically want neuropsychiatric markers like SLC6A4 or HTR2A, Genomind includes more of those than either of the others. If you want the broadest pharmacogenetic coverage at the lowest cost, and you already have consumer genotyping data, Gene2Rx is the obvious choice. For many people, all three produce the same underlying metabolizer phenotype information. The choice comes down to price, workflow, whether you want a clinical-grade fresh sample, and which additional genes you want.

The clinical-impact genes are covered by all three services. The differences are in which additional genes each service includes and whether the additional coverage has clinical evidence behind it.

The metabolizer phenotype a test produces is a function of your DNA, not the brand of the test, and all three map it to the same CPIC^[5] and FDA guidelines. Two services looking at the same variants in the same sample will return the same CYP2D6 or CYP2C19 phenotype. Where services legitimately differ is in which medications they map that phenotype to, which additional markers they include, and whether they run a fresh clinical-grade sample that can resolve copy-number variation.

If you have not yet done any pharmacogenetic testing, the choice comes down to what you need. For direct psychiatric prescribing in an established relationship with a GeneSight-comfortable clinician, GeneSight. For specific neuropsychiatric research markers like SLC6A4, Genomind. For broad coverage, low cost, and existing genetic data, Gene2Rx. All three are legitimate choices made by different groups of patients for different reasons.

• Looking for a GeneSight Alternative? Here's the Short Answer
• Looking for a Genomind Alternative? Here's What to Know
• 23andMe Pharmacogenetics: How to Get a Drug Response Report From Your Existing Data
• AncestryDNA for Drug Testing: Get Pharmacogenetics From Your Ancestry Data
• MyHeritage Pharmacogenetics: Use Your MyHeritage DNA for a Drug Response Report
• Nebula Genomics Pharmacogenetics: How to Get a Drug Response Report From Your WGS Data

They overlap heavily on the core drug-metabolizing cytochrome P450 genes (CYP2D6, CYP2C19, CYP2C9, etc.) and on HLA alleles relevant to hypersensitivity. They differ in the neuropsychiatric markers they include: GeneSight's panel emphasizes SLC6A4, HTR2A, UGT1A4, UGT2B15, and OPRM1; Genomind's panel emphasizes ADRA2A, CACNA1C, MTHFR, and the serotonin transporter. The exact panel for each company has evolved over time, so check the current version.

Accuracy in pharmacogenetic testing means correctly calling the genetic variants. All three services do this reliably. The differences are not about accuracy but about panel composition, report format, coverage, and cost. A CYP2D6 poor metabolizer identified by any of these tests is a CYP2D6 poor metabolizer. The one technical edge a clinical lab test has is that a fresh, clinical-grade sample can resolve CYP2D6 copy-number changes that consumer genotyping data cannot.

Gene2Rx, by a large margin. Starting at $5 for a starter report and up to $49 for the full report, Gene2Rx's direct-to-consumer model is significantly cheaper than GeneSight or Genomind because it uses your existing genetic data rather than performing a new clinical lab test.

You can, but there is usually not much point. A CYP2D6 or CYP2C19 phenotype determined by one test will be the same phenotype determined by another. The one scenario where it makes sense is if you already have a GeneSight or Genomind report that is narrowly focused and you want broader coverage. Gene2Rx can interpret your existing 23andMe or AncestryDNA data to cover medications outside the psychiatric panel, without requiring a new clinical test.